Kidney Cancer
Principles and Practice
1st Edition
Published on 10. January 2012
VIII, 301 pages
978-3-642-21858-3 (ISBN)
Description
This interdisciplinary textbook encompasses all clinically relevant aspects of the disease and is designed to be as user-friendly as possible in order to meet the needs of the busy practitioner. To this end, the informative text is complemented by helpful boxed sections that present essential 'take home' points and illustrative patient-oriented cases. Original high-quality images, some in color, are included whenever necessary to simplify particularly complex material. The authors are an international group of acknowledged experts in kidney cancer epidemiology, molecular biology, pathology, diagnosis, clinical features, staging, prognostic and predictive factors, surgery, systemic therapy, and emerging investigational approaches, among others. This clinically oriented volume will be of great interest to clinicians, researchers, residents, and fellows, as well as to students and knowledgeable lay people.
More details
Series
Language
English
Place of publication
Berlin
Germany
Publishing group
Springer Berlin
Target group
Professional and scholarly
Product notice
Reflowable
Illustrations
VIII, 301 p. 49 illus., 36 illus. in color.
File size
7,22 MB
ISBN-13
978-3-642-21858-3 (9783642218583)
DOI
10.1007/978-3-642-21858-3
Schweitzer Classification
Other editions
Additional editions
Book
01/2012
Springer
€106.95
Article exhausted; check for reprint
Content
Epidemiology and biology: Rencal cell cancer (RCC) epidemiology. Pathology of RCC. Molecular biology of RCC. Prognostic and predictive biomarkers.- Clinical considerations: Clinical presentation and staging.- Surgical and local control modalities: Surgical approaches to early stage RCC. Palliative debulking nephrectomy in advanced stage RCC. Metastasectomy. Energy ablative techniques in RCC. Radiation therapy in RCC.- Systemic therapy considerations: Cytokines and other immune therapies in RCC. Anti-VEGF therapy in RCC. The role of mTOR inhibitors and PI3K pathway blockade in RCC. Sequential versus combination strategies. Presurgical therapy. Toxicity management for patients on targeted therapy. Emerging agents in RCC.
